AstraZeneca’s AZD5004 Study Completion: Key Insights for Investors

AstraZeneca ((AZN)) announced an update on their ongoing clinical study.

AstraZeneca recently completed a Phase I study titled A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004. The study aimed to assess how hepatic impairment affects the pharmacokinetics, safety, and tolerability of AZD5004, a drug under investigation, in participants with varying degrees of liver function.

The intervention involved administering a single oral dose of AZD5004 to participants. The drug is intended to be evaluated for its safety and efficacy in individuals with different levels of hepatic impairment.

The study was non-randomized and open-label, meaning all participants and researchers knew the treatment being administered. It was structured in parallel groups, with participants divided based on their liver function—mild, moderate, severe impairment, and normal function. The primary aim was to assess treatment effects.

The study began on December 17, 2024, and was last updated on October 14, 2025. These dates are crucial as they mark the progress and current status of the study, which is now completed.

This update could influence AstraZeneca’s stock performance positively, as successful results may enhance investor confidence. In the competitive pharmaceutical industry, advancements in drug development can significantly impact market dynamics.

The study is now completed, with further details available on the ClinicalTrials portal.